Table 1.
Patient and transplant characteristics
| Factors | N (%) |
|---|---|
| Total | 370 |
| Year of transplant | |
| 1990–1995 | 119 (32%) |
| 1996–2000 | 106 (29%) |
| 2001–2005 | 69 (19%) |
| 2006–2010 | 30 (8%) |
| 2011–2016 | 46 (12%) |
| Age | |
| <2 years | 67 (18%) |
| 2–9 years | 168 (45%) |
| 10–17 years | 135 (36%) |
| Median, years (range) | 7 (0.2–17.95) |
| Gender | |
| Male | 244 (66%) |
| Female | 126 (34%) |
| Disease | |
| Acute lymphoblastic leukemia | 91 (25%) |
| Acute myelogenous leukemia | 60 (16%) |
| CML/JMML | 19 (5%) |
| Myelodsyplastic syndrome | 19 (5%) |
| Hodgkins lymphoma/Non-Hodgkins lymphoma | 8 (2%) |
| Inborn error of metabolism | 94 (25%) |
| Fanconi anemia | 27 (7%) |
| Aplastic anemia | 21 (6%) |
| Immune deficiency | 27 (7%) |
| Epidermolysis bullosa | 4 (1%) |
| Disease risk | |
| Standard risk malignancy | 132 (36%) |
| High risk malignancy | 65 (18%) |
| Nonmalignant disease | 173 (47%) |
| CMV serostatus | |
| Recipient negative, donor negative | 167 (45%) |
| Recipient negative and/or donor positive | 203 (55%) |
| Donor type | |
| HLA-matched sibling | 61 (16%) |
| HLA-mismatched sibling | 8 (2%) |
| Well matched URD | 48 (13%) |
| Partial matched URD | 56 (15%) |
| HLA-mismatched URD | 65 (18%) |
| Single UCB | 97 (26%) |
| Double UCB | 35 (9%) |
| Conditioning | |
| Myeloablative | 351 (95%) |
| Reduced intensity | 19 (5%) |
| GVHD prophylaxis | |
| Cyclosporine or tacrolimus containing | 290 (78%) |
| T-cell depletion | 65 (18%) |
| Methotrexate alone | 14 (4%) |
| Sirolimus and mycophenolate mofetil | 1 (0.3%) |
Standard risk = acute leukemia in CR1 or CR2, CML in first chronic phase, MDS without excess blasts or nonmalignant diseases. High risk malignancy = all others
CML chronic myelogenous leukemia, JMML juvenile myelomonocytic leukemia